SHIJIAZHUANG CITY, China
Lianhua Qingwen Capsules, an innovative patent traditional Chinese medicine (TCM), is produced by China’s Yiling Pharmaceutical under the guidance of TCM Collateral Disease Theory.
This medicine has been widely used in the treatment of influenza caused by toxic heat attacking lung, with symptoms of fever, aversion to cold, muscular soreness, nasal obstruction and running nose, cough, headache, dry and sore throat, reddish tongue, yellow tongue coating or greasy tongue coating. It has been listed in the authoritative guidebook Common Drugs for Chinese Families 2019-2020 due to its extensive use scenarios, good efficacy, and wide acceptance by consumers.
The efficacy of Lianhua Qingwen is not bragged, but with adequate scientific evidence. Yiling Pharmaceutical has taken a lead in the Evidence-based Medicine research in China. The Evidence-based Medicine refers to the use of large-scale, multi-sample, randomized, double-blind clinical trial to test the efficacy of drugs, which is currently the most scientific and impartial drug efficacy evaluation approach. Up to now several Evidence-based Medicine clinical trials have accumulated plenty of proof for its efficacy.
The Philippine Food and Drug Administration has issued approval document for Lianhua Qingwen, and it has been officially launched on November 23. The registration number is THPR-50 and the product category is traditional herbal drugs. The Philippine consumers can now buy it in Mercury Drug, Southstar Drug and Watson since then, and its price is only 288 pesos per pack.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201224005059/en/
CONTACT
First name: Li
Last Name: Kristy
E-mail:kristyli@chuhaimedia.com.cn
Phone No.: +86 85962566
